loading page

A Surgery-based Comprehensive Treatment Improved Prognosis in Patients with Stage IIIC Cervical Squamous Carcinoma: A Single Center Retrospective Study
  • +10
  • Hui WANG,
  • Shen LUO,
  • Ling QIU,
  • Hao FENG,
  • Shurong ZHU,
  • Xiaolei LIN,
  • Yanan YOU,
  • Ming LI,
  • Yuanzhou Peng,
  • Weili Yan,
  • Yan Du,
  • Hua JIANG,
  • Xin WU
Hui WANG
Obstetrics and Gynecology Hospital of Fudan University
Author Profile
Shen LUO
Obstetrics and Gynecology Hospital of Fudan University
Author Profile
Ling QIU
Obstetrics and Gynecology Hospital of Fudan University
Author Profile
Hao FENG
Obstetrics and Gynecology Hospital of Fudan University
Author Profile
Shurong ZHU
University of Saskatchewan School of Public Health
Author Profile
Xiaolei LIN
Fudan University Shanghai Key Laboratory of Data Science
Author Profile
Yanan YOU
Obstetrics and Gynecology Hospital of Fudan University
Author Profile
Ming LI
Obstetrics and Gynecology Hospital of Fudan University
Author Profile
Yuanzhou Peng
Children's Hospital of Fudan University
Author Profile
Weili Yan
Children's Hospital of Fudan University
Author Profile
Yan Du
Obstetrics and Gynecology Hospital of Fudan University
Author Profile
Hua JIANG
Obstetrics and Gynecology Hospital of Fudan University
Author Profile
Xin WU
Obstetrics and Gynecology Hospital of Fudan University

Corresponding Author:[email protected]

Author Profile

Abstract

Objective: This study intended to analyze the prognosis of patients with stage IIIC squamous cervical cancer who underwent the Obstetrics and Gynecology Hospital of Fudan University (FUOG) Treatment, and explored the factors influencing their prognosis. Design: A retrospective study. Setting: A large tertiary hospital specializing in obstetrics and gynecology in China. Population or Sample: This study collected data from 717 patients with stage IIIC squamous cervical cancer who underwent FUOG Treatment in our hospital from January 2016 to December 2020. Methods: Kaplan-Meier method was used to estimate progression-free survival (PFS) and overall survival (OS). Stratified analysis was performed to examine the risk factors. Main Outcome Measures: The main outcomes were 3-year PFS and OS. Results: The 3-year OS was 90.9% for patients with stage IIIC squamous cervical cancer, 91.5% for stage IIIC1 and 83.2% for stage IIIC2, respectively. The 3-year PFS was 84.8%, 85.3% for stage IIIC1 and 78.8% for stage IIIC2, respectively. Undifferentiated squamous carcinoma was an independent prognostic factor for OS (HR: 5.793, p=0.0064) and PFS (HR: 4.663, p=0.0033). Postoperative patients with standard adjuvant therapy had better 3-year OS outcomes than patients with non-standard therapy (88.4% vs 73.4%, p=0.007). Patients with undifferentiated type (OR=8.471), positive parietal infiltration (OR=3.339), or tumor infiltration depth of 1/3-2/3 (OR=5.454) were more likely to have distant recurrence. Conclusions: The prognosis of patients with stage IIIC cervical squamous carcinoma treated with the FUOG Treatment is satisfactory. However, risk factors such as undifferentiated type, positive paracervical infiltration, and non-standard adjuvant therapy can negatively affect prognosis.